Key Takeaways:

  • Genomics launched Mystra, an AI-powered genetics platform.
  • Mystra uses trillions of genetic data points to find drug targets.
  • The platform’s AI delivers fast, evidence-based insights for drug development.
  • Genomics aims to speed up and improve the safety of new medicines.

 

 

US Biotech company Genomics has announced the launch of a new target discovery and validation platform powered by AI. The company officially unveiled the platform during a presentation at the 2025 meeting of the American Society of Human Genetics in Boston.

Trillions of rows of data

Dave Thornton, President at Genomics, said: "For over a decade, we have been meticulously building and using an unparalleled platform of genetic insights to accelerate our own collaborations with biopharma partners."

Genomics say that their platform, dubbed ‘Mystra’ uses the ‘world’s largest and most diverse’ database of genotype-phenotype associations to make educated predictions of possible drug targets. This includes trillions of rows of data from over 20,000 genome-wide association studies (GWASs).

In a news release, the company said that Mystra “builds on and augments these datasets, providing extensive, powerful insights into human biology, with relevant information for drug development and critical insights into disease mechanisms supported by evidence from studies of genetic variation.”

Guided by AI

Mystra is uses Genomics’ proprietary AI algorithms to deliver insights into disease mechanisms backed up by genetic evidence. Enhanced by advanced machine learning methods, this platform provides efficient and comprehensive analyses to support drug development.

“Today, we are making this breakthrough technology available to the statistical geneticists throughout the R&D community. Mystra transforms fragmented data into actionable, high-conviction insights, empowering statistical geneticists and life sciences companies to make real-time decisions that were previously impossible,” said Thornton.

“We are changing the trajectory of drug development - to bring tomorrow's medicine for the patients of today, safer and faster."